Porphyrin-engineered Nanoscale Metal-organic Frameworks: Enhancing Photodynamic Therapy and Ferroptosis in Oncology
Overview
Affiliations
Photodynamic therapy and ferroptosis induction have risen as vanguard oncological interventions, distinguished by their precision and ability to target vulnerabilities in cancer cells. Photodynamic therapy's non-invasive profile and selective cytotoxicity complement ferroptosis' unique mode of action, which exploits iron-dependent lipid peroxidation, offering a pathway to overcome chemoresistance with lower systemic impact. The synergism between photodynamic therapy and ferroptosis is underscored by the depletion of glutathione and glutathione peroxidase four inhibitions by photodynamic therapy-induced reactive oxygen species, amplifying lipid peroxidation and enhancing ferroptotic cell death. This synergy presents an opportunity to refine cancer treatment by modulating redox homeostasis. Porphyrin-based nanoscale metal-organic frameworks have unique hybrid structures and exceptional properties. These frameworks can serve as a platform for integrating photodynamic therapy and ferroptosis through carefully designed structures and functions. These nanostructures can be engineered to deliver multiple therapeutic modalities simultaneously, marking a pivotal advance in multimodal cancer therapy. This review synthesizes recent progress in porphyrin-modified nanoscale metal-organic frameworks for combined photodynamic therapy and ferroptosis, delineating the mechanisms that underlie their synergistic effects in a multimodal context. It underscores the potential of porphyrin-based nanoscale metal-organic frameworks as advanced nanocarriers in oncology, propelling the field toward more efficacious and tailored cancer treatments.
Recent Advances in Glutathione Depletion-Enhanced Porphyrin-Based nMOFs for Photodynamic Therapy.
Gong B, Zhang Q, Chen J, Qu Y, Luo X, Wang W Pharmaceutics. 2025; 17(2).
PMID: 40006611 PMC: 11860060. DOI: 10.3390/pharmaceutics17020244.
Qi C, Chen J, Qu Y, Luo X, Wang W, Zheng X Pharmaceutics. 2025; 16(12.
PMID: 39771603 PMC: 11678282. DOI: 10.3390/pharmaceutics16121625.
Zou Y, Wu J, Zhang Q, Chen J, Luo X, Qu Y Front Pharmacol. 2024; 15:1505212.
PMID: 39697550 PMC: 11652162. DOI: 10.3389/fphar.2024.1505212.
Metal-organic frameworks as nanoplatforms for combination therapy in cancer treatment.
Lafi Z, Matalqah S, Abu-Saleem E, Asha N, Mhaidat H, Asha S Med Oncol. 2024; 42(1):26.
PMID: 39653960 DOI: 10.1007/s12032-024-02567-3.